Air Liquide reports growth performance results 2010

Air Liquide reports growth performance results 2010

5:30 PM, 25th May 2011
Air Liquide reports growth performance results 2010

  • New production unit start-ups at a rate of two per month
  • Expansion in Developing economies: new sites in Panama and Turkey, new contracts in India, China, Poland, Russia
  • Acquisitions in Healthcare: Australia, South Korea, France
  • Projects in Energy and Environment: Carbon Capture and Storage in the US, hydrogen in Saudi Arabia


PARIS, FRANCE: The 2010 consolidated revenue of Air Liquide amounts to € 13,488 million. The progressive recovery in gas and services, which increased +10.3 per cent on a comparable basis, accelerated quarter-by-quarter in all regions, especially in the developing economies (+29 per cent on a comparable basis). Highlights of the year included strong growth in Large Industries, with a record number of start-ups and ramp-ups of new units; sustained performance in Industrial Merchant; confirmation of a rebound in electronics; and solidity in Healthcare.

Net profit (group share) posts an increase of +14.1 per cent, above the group’s historical performance, and the operating margin reached 16.7 per cent, up +40 basis points compared to 2009, in part due to continued efficiency gains totaling € 280 million for the year. The net debt stands at € 5,039 million, down by € 183 million, at constant exchange rates, leading to a gearing ratio of 55 per cent. Return on capital employed increased to 12.1 per cent.

“The year 2010 highlights include the return to more sustained growth in all of our businesses and geographies, and stronger overall performance. The group has expanded its positions in developing economies, which represent 19 per cent of gas and services sales for the year. This performance, together with our ongoing efficiency programmes, led to further improvement in operating results and a strengthened balance sheet,” said Benoît Potier, Chairman and CEO, Air Liquide Group.


He added, “The recovery of the long-term investment cycle, as demonstrated by the signing of new contracts in all of our businesses, has led us to double the amount of our investment decisions compared to 2009, reaching € 2.2 billion. The new momentum is already established, spurred by the ALMA 2015 programme, and supported by our five growth drivers (energy, environment, developing economies, health, high-tech). This momentum will allow us to seize many growth opportunities and accelerate our long-term development. Assuming normal economic conditions, the group is confident to continue steady growth of net profit in 2011.”

(C) WOC News




Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Rhodia to increase production capacity of highly dispersible Silica

LYON, FRANCE: Rhodia is investing in its Chicago Heights (USA) and Collonges-au-Mont-d’Or (France) plants to increase its highly dispersible s ...

Read more
Eastman Chemical elects Brett D Begemann as new Director

KINGSPORT, US: Eastman Chemical Company has elected Brett D Begemann as a Director. Currently Begemann, 50, is Executive VP and Chief Commercial Off ...

Read more
Albemarle reports record quarterly sales, income and EPS

Record quarterly net sales performance of $ 697 million, up 20 per cent from prior year net sales of $ 580 million, including record net sales p ...

Read more
Hosni Mubarak steps down as president of Egypt

  LONDON, UNITED KINGDOM: Hosni Mubarak has stepped down as president of Egypt after more than two weeks of anti-government protests which have ...

Read more
Bayer MaterialScience starts new polyisocyanates unit in India

Facility for production of polyurethane raw materials for coatings and adhesives.   ANKLESHWAR, INDIA: Bayer MaterialScience has inaugurated ...

Read more
Evonik to buy Boehringer Ingelheim’s Resomer business

High growth potential for Evonik’s pharmaceuticals business A new polymer platform broadening the pharmaceutical excipient business Expansio ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X